Skip to content

Use of Melatonin for Preventing POCD in Transurethral Prostate Resection Under Spinal Anesthesia

Use of Melatonin for Prevention of POCD After TURP Surgery Under Spinal Anesthesia for Elderly Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03966950
Enrollment
104
Registered
2019-05-29
Start date
2017-06-26
Completion date
2021-11-26
Last updated
2019-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction, Melatonin, Postoperative Complications, Prostate Hyperplasia

Keywords

Melatonin, Cognitive Dysfunction

Brief summary

This study aims to evaluate the possible effect of melatonin on prevention of cognitive dysfunction in the postoperative period of elderly patients undergoing transurethral resection of the prostate (TURP) under spinal anesthesia

Detailed description

TURP is the most common surgical procedure performed on male patients over 60 years of age to treat benign prostatic hyperplasia. One of the concerns, since it compromises the quality of life, is postoperative cognitive dysfunction. It can be due to TURP Syndrome or to other causes, like changing the routine and circadian rhythm for patients with more susceptibility. The investigators postulate that melatonin premedication and use during the perioperative period could avoid cognitive impairment in patients undergoing TURP surgery that didn't develop major complications, like TURP Syndrome. Since anesthestic technic could also influence the outcome of POCD, only patients undergoing spinal anesthesia were included in the study,

Interventions

DIETARY_SUPPLEMENTmelatonin

melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.

DRUGPlacebo oral tablet

placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

triple masking

Intervention model description

randomized, parallel assignment

Eligibility

Sex/Gender
MALE
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

patients over 60 years who underwent elective surgery for transurethral prostate ressection under spinal anesthesia. MME \> 18 (for those who had less than 4 years of formal education ) or MME \> 23 (for those with 4 or more years of formal education)

Exclusion criteria

MME \< 18 (for those who had less than 4 years of formal eduaction) or 23 (for those with 4 years or more of formal eduacation); History of cancer, brain disease, seizure, Parkinson, dementia, hallucination or any disorder that affects cognition before the surgery. Lack of proficiency in portuguese mild or severe hearing loss or blindness.

Design outcomes

Primary

MeasureTime frameDescription
early postoperative cognitive dysfunction30 daysa full battery of neuropsychological tests including FOME (Fuld Object memory evaluation test), Stroops colours world test, Trail making test and Wais-III were applied in the preoperative day and compared to the 30-postoperative day evaluation. A z score decline higher than 0,5 in two different domains defines an early postoperative cognitive dysfunction

Secondary

MeasureTime frameDescription
late postoperative cognitive dysfunction180 daysneuropsychological testings (WAIS - III, Trail Making Test, Stroop Colours Word Test and Fuld Object Memory Evaluation Test) were applied after 6 months of the surgery and the z score is compared to the preoperative evaluation- a z score decline higher than 0,5 in two different domains can define a late postoperative cognitive dysfunction

Countries

Brazil

Contacts

Primary ContactMaria JC Carmona, PHD
maria.carmona@hc.fm.usp.br+5511996450293
Backup ContactCristiane Tavares, MD
cristianetav@gmail.com+5511983039765

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026